Benefits and risks of thrombolytic, anticoagulant and antiplatelet therapies in atrial fibrillation
- PMID: 8439785
Benefits and risks of thrombolytic, anticoagulant and antiplatelet therapies in atrial fibrillation
Abstract
The decision whether to anticoagulate is a common dilemma when faced with a patient with atrial fibrillation. This article reviews the role of warfarin and antiplatelet agents and recommends a rational approach to the management of this condition.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical